---
schema_version: "secwatch.filing_event.v1"
accession: "0001826667-25-000024"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:13:49.656491+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TriSalus reports FY 2024 revenue $29.4M (+59% YoY); delays 10-K due to accounting errors

## Summary
- Q4 revenue $8.3M, FY revenue $29.4M (59% growth YoY); gross margin 86%.
- Filing a Form 12b-25 for late 10-K due to errors in stock-based compensation and R&D expense timing.
- Reaffirms 2025 guidance: >50% revenue growth, >20% OpEx reduction, positive EBITDA, positive cash flow H2 2025.
- Cash $8.5M at Dec 31, plus $15M available under $50M OrbiMed credit facility.
- Launched TriNav LV and TriGuide catheters; DELIVER program expanding addressable market to >$1B.

## SEC filing metadata
- accession: 0001826667-25-000024
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000024/0001826667-25-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000024/tlsi-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001826667-25-000024
- JSON: https://secwatch.observer/filing/0001826667-25-000024.json
- Plain text: https://secwatch.observer/filing/0001826667-25-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.